No shit it's effective, America's best and brightest doctors already said so. Did the media think Trump was running petri tests himself in the oval office? Where do they think he got this info?
In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin, the team found a clinical improvement in all but one 86 year-old patient who died, and one 74-year old patient still in intensive care unit. The team also found that, by administering hydroxychloroquine combined with azithromycin, they were able to observe an improvement in all cases, except in one patient who arrived with an advanced form, who was over the age of 86, and in whom the evolution was irreversible, according to a new paper published today in IHU Méditerranée Infection.
Welp sorry giez it didn't cure someone already terminal better luck next time Drumpfofofpfpfp
Because it's good research methodology and provides high quality evidence that the treatment works (or doesn't work, or works as well as something else you're trying). Otherwise you're just slinging unproven treatments around and muddying the water. Will have to read this second paper, hopefully better than the first, where they dropped the people that died or got upgraded to ICU (worsened) and claimed that "everyone [that remained in the study] got better."
A total of 26 patients received hydroxychloroquine and 16 were control patients. Six hydroxychloroquine-treated patients were lost in follow-up during the survey because of early cessation of treatment. Reasons are as follows: three patients were transferred to intensive care unit, including one transferred on day2 post-inclusion who was PCR-positive on day1, one transferred on day3 post-inclusion who was PCR-positive on days1-2 and one transferred on day4 post-inclusion who was PCR-positive on day1 and day3; one patient died on day3 post inclusion and was PCR-negative on day2; one patient decided to leave the hospital on day3 post-inclusion and was PCR-negative on days1-2; finally, one patient stopped the treatment on day3 post-inclusion because of
nausea and was PCR-positive on days1-2-3.
Page 21 & 22 which shows their data shows that they only analyzed 20 of the HCQ treated patients, not the full 26 that received it, so they dropped 6 as they mentioned. 4 of the 6 people they dropped from the experimental group worsened.
In our Institute, which contains 75 individual rooms for treating highly contagious patients, we currently have a turnover rate of 1/3 which allows us to receive a large number of these contagious patients with early discharge."
This is the key. High turnover would alleviate overwhelming the hospitals.
There's an interview from this guy with "The Parisian" newspaper, from like, less than a week ago.
Didier Raoult gives no fucks about being politically correct.
It's a very good read. Calls world leaders stupid, says we've known about hydroxychloroquine being effective against Sars viruses since the early 2000s, baffled that people couldn't do a simple search to find it.
The way he answers is very direct and no non-sense. It's a good read.
The fact that this was so difficult to find tends to make me more of a conspiracy theorist about all this. Sigh. There should be links to this interview in all our major publications.
We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year-old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. This allowed patients to rapidly de discharge from highly contagious wards with a mean length of stay of five days. We believe other teams should urgently evaluate this cost-effective therapeutic strategy, to both avoid the spread of the disease and treat patients as soon as possible before severe respiratory irreversible complications take hold.
Results
A total of 80 patients with confirmed COVID-19 were hospitalised at the Méditerranée Infection University Hospital Institute (N=77) and at a temporary COVID-19 unit (N=3) with dates of entry from 3–21 March 2020. All patients who received treatment with hydroxychloroquine and azithromycin (16) for at least three days and who were followed-up for at least six days were included in this analysis. The median age of patients was 52 years (ranging from 18 to 88 years) with a M/F sex ratio of 1.1. 57.5% of these patients had at least one chronic condition known to be a risk factor for the severe form of COVID-19 with hypertension, diabetes and chronic respiratory disease being the most frequent. The time between the onset of symptoms and hospitalisation was on average five days, with the longest time being 17 days. 53.8% of patients presented with LRTI symptoms and 41.2% with URTI symptoms. Only 15% of patients were febrile. Four patients were asymptomatic carriers. The majority of patients had a low NEWS score (92%) and 53.8% of patients had LDCT compatible with pneumonia. The mean PCR Ct value was 23.4.
Hydroxychloroquine and azithromycin combined treatment
The mean time between the onset of symptoms and the initiation of treatment was 4.9 days and most patients were treated on the day of admission or on the day after (93.7%). A total of 79/80 patients received treatment on a daily basis throughout the whole study period, which lasted a maximum of ten days. In one patient, the treatment had to be stopped on Day4 because, although it was well tolerated there was a potential risk of interaction with another drug. Adverse events were rare and minor.
Clinical course
The majority (65/80, 81.3%) of patients had favourable outcome and were discharged from our unit at the time of writing with low NEWS scores (61/65, 93.8%). Only 15% required oxygen therapy. Three patients were transferred to the ICU, of whom two improved and were then returned to the ID ward. One 74 year-old patient was still in ICU at the time of writing. Finally, one 86 year-old patient who was not transferred to the ICU, died in the ID ward
In conclusion
We confirm the efficacy of hydroxychloroquine associated with azithromycin in the treatment of COVID-19 and its potential effectiveness in the early impairment of contagiousness. Given the urgent therapeutic need to manage this disease with effective and safe drugs and given the negligible cost of both hydroxychloroquine and azithromycin, we believe that other teams should urgently evaluate this therapeutic strategy both to avoid the
spread of the disease and to treat patients before severe irreversible respiratory complications take hold.
No shit it's effective, America's best and brightest doctors already said so. Did the media think Trump was running petri tests himself in the oval office? Where do they think he got this info?
'Yuge meme potential.
Do'nt wait for stinky fingers Don Lemonparty to admit Trump was right
"But muh 30 patient, totally not biased Chinese gov backed study said it was useless!"
Sick how blatant this coordinated media attack is; they'd rather thousands die just for the headlines...
Trump should start saying it doesn't work, and see how quick they flip-flop!
The study said that hydroxychloroquine by itself it was about as effective as the other effective treatment, which was the AIDS retrovirus drugs.
Except, you know, much cheaper, not under patent, widely available and not poised to make pharmaceuticals any money.
Only a retard would consider those results a negative, which is I guess why it was a such a big deal in the media.
Welp sorry giez it didn't cure someone already terminal better luck next time Drumpfofofpfpfp
/s
i wish he would do a control arm.
Why, that's bad. Would you want to be on the control side?
Keep medicating every patient who wants it.
Because it's good research methodology and provides high quality evidence that the treatment works (or doesn't work, or works as well as something else you're trying). Otherwise you're just slinging unproven treatments around and muddying the water. Will have to read this second paper, hopefully better than the first, where they dropped the people that died or got upgraded to ICU (worsened) and claimed that "everyone [that remained in the study] got better."
Didn't know they dropped the people that got into ICU..... How.many of them were dropped?
But my point stands and that was the thinking of the Doc who made the experiment, he said we have to help everyone.
Source: https://drive.google.com/file/d/186Bel9RqfsmEx55FDum4xY_IlWSHnGbj/view
Page 10:
Page 21 & 22 which shows their data shows that they only analyzed 20 of the HCQ treated patients, not the full 26 that received it, so they dropped 6 as they mentioned. 4 of the 6 people they dropped from the experimental group worsened.
When can we expect the results of the fish tank cleaner study? So far two people who took it are no longer worried about china virus.
This is the key. High turnover would alleviate overwhelming the hospitals.
Exactly. This is YUGE!
https://thedonald.win/p/FMO7SDQd/hydroxychloroquine-101/c/
There's an interview from this guy with "The Parisian" newspaper, from like, less than a week ago.
Didier Raoult gives no fucks about being politically correct.
It's a very good read. Calls world leaders stupid, says we've known about hydroxychloroquine being effective against Sars viruses since the early 2000s, baffled that people couldn't do a simple search to find it.
The way he answers is very direct and no non-sense. It's a good read.
Found it, and a translation, but it wasn’t easy.
https://thesaker.is/interview-with-professor-didier-raoult-in-the-parisien-newspaper-22-march-2020/
The fact that this was so difficult to find tends to make me more of a conspiracy theorist about all this. Sigh. There should be links to this interview in all our major publications.
FROM THE PAPER ITSELF :
[condense and edited, most of paper not included]
Abstract
We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year-old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. This allowed patients to rapidly de discharge from highly contagious wards with a mean length of stay of five days. We believe other teams should urgently evaluate this cost-effective therapeutic strategy, to both avoid the spread of the disease and treat patients as soon as possible before severe respiratory irreversible complications take hold.
Results
A total of 80 patients with confirmed COVID-19 were hospitalised at the Méditerranée Infection University Hospital Institute (N=77) and at a temporary COVID-19 unit (N=3) with dates of entry from 3–21 March 2020. All patients who received treatment with hydroxychloroquine and azithromycin (16) for at least three days and who were followed-up for at least six days were included in this analysis. The median age of patients was 52 years (ranging from 18 to 88 years) with a M/F sex ratio of 1.1. 57.5% of these patients had at least one chronic condition known to be a risk factor for the severe form of COVID-19 with hypertension, diabetes and chronic respiratory disease being the most frequent. The time between the onset of symptoms and hospitalisation was on average five days, with the longest time being 17 days. 53.8% of patients presented with LRTI symptoms and 41.2% with URTI symptoms. Only 15% of patients were febrile. Four patients were asymptomatic carriers. The majority of patients had a low NEWS score (92%) and 53.8% of patients had LDCT compatible with pneumonia. The mean PCR Ct value was 23.4.
Hydroxychloroquine and azithromycin combined treatment
The mean time between the onset of symptoms and the initiation of treatment was 4.9 days and most patients were treated on the day of admission or on the day after (93.7%). A total of 79/80 patients received treatment on a daily basis throughout the whole study period, which lasted a maximum of ten days. In one patient, the treatment had to be stopped on Day4 because, although it was well tolerated there was a potential risk of interaction with another drug. Adverse events were rare and minor.
Clinical course
The majority (65/80, 81.3%) of patients had favourable outcome and were discharged from our unit at the time of writing with low NEWS scores (61/65, 93.8%). Only 15% required oxygen therapy. Three patients were transferred to the ICU, of whom two improved and were then returned to the ID ward. One 74 year-old patient was still in ICU at the time of writing. Finally, one 86 year-old patient who was not transferred to the ICU, died in the ID ward
In conclusion
We confirm the efficacy of hydroxychloroquine associated with azithromycin in the treatment of COVID-19 and its potential effectiveness in the early impairment of contagiousness. Given the urgent therapeutic need to manage this disease with effective and safe drugs and given the negligible cost of both hydroxychloroquine and azithromycin, we believe that other teams should urgently evaluate this therapeutic strategy both to avoid the spread of the disease and to treat patients before severe irreversible respiratory complications take hold.